Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	histone H3K9me2/H3K9me3 demethylase activity	KDM4C KDM4E KDM4D KDM4B	1.12e-08	6	106	4	GO:0140684
GeneOntologyMolecularFunction	histone H3K9 demethylase activity	KDM4C KDM4E KDM4D KDM4B	7.21e-07	14	106	4	GO:0032454
GeneOntologyMolecularFunction	histone H3 demethylase activity	KDM4C KDM4E KDM4D KDM4B	1.39e-05	28	106	4	GO:0141052
GeneOntologyMolecularFunction	histone demethylase activity	KDM4C KDM4E KDM4D KDM4B	2.11e-05	31	106	4	GO:0032452
GeneOntologyMolecularFunction	protein demethylase activity	KDM4C KDM4E KDM4D KDM4B	2.41e-05	32	106	4	GO:0140457
GeneOntologyMolecularFunction	acyl-L-homoserine-lactone lactonohydrolase activity	PON1 PON2	8.35e-05	3	106	2	GO:0102007
GeneOntologyMolecularFunction	lactonohydrolase activity	PON1 PON2	8.35e-05	3	106	2	GO:0046573
GeneOntologyMolecularFunction	demethylase activity	KDM4C KDM4E KDM4D KDM4B	8.65e-05	44	106	4	GO:0032451
GeneOntologyMolecularFunction	stearoyl-CoA 9-desaturase activity	SCD FADS2	1.66e-04	4	106	2	GO:0004768
GeneOntologyMolecularFunction	acyl-CoA desaturase activity	SCD FADS2	2.76e-04	5	106	2	GO:0016215
GeneOntologyMolecularFunction	2-oxoglutarate-dependent dioxygenase activity	KDM4C KDM4E KDM4D KDM4B	3.96e-04	65	106	4	GO:0016706
GeneOntologyMolecularFunction	arylesterase activity	PON1 PON2	4.13e-04	6	106	2	GO:0004064
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	KDM4C KDM4E KDM4D SCD FADS2 KDM4B	5.94e-04	194	106	6	GO:0016705
GeneOntologyMolecularFunction	1-phosphatidylinositol-4-phosphate 5-kinase activity	PIP5K1A PIPSL	9.81e-04	9	106	2	GO:0016308
GeneOntologyMolecularFunction	nuclease activity	EXOSC10 DCPS TATDN2 DIS3 AGO3 DCLRE1A	1.46e-03	231	106	6	GO:0004518
GeneOntologyMolecularFunction	exonuclease activity	EXOSC10 DCPS DIS3 DCLRE1A	1.46e-03	92	106	4	GO:0004527
GeneOntologyMolecularFunction	histone H3K36 demethylase activity	KDM4C KDM4B	1.49e-03	11	106	2	GO:0051864
GeneOntologyMolecularFunction	RNA exonuclease activity	EXOSC10 DCPS DIS3	1.75e-03	45	106	3	GO:0004532
GeneOntologyMolecularFunction	dioxygenase activity	KDM4C KDM4E KDM4D KDM4B	1.85e-03	98	106	4	GO:0051213
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water	SCD FADS2	2.10e-03	13	106	2	GO:0016717
GeneOntologyMolecularFunction	peptidase activity	PCSK2 PITRM1 ADAM18 OTUD1 ADAMTS12 CNTNAP5 VASH2 MMP8 MYRF VCPIP1	2.51e-03	654	106	10	GO:0008233
GeneOntologyCellularComponent	pericentric heterochromatin	KDM4C KDM4E KDM4D KDM4B	2.01e-05	32	106	4	GO:0005721
Domain	JmjN	KDM4C KDM4E KDM4D KDM4B	1.86e-07	10	104	4	SM00545
Domain	JmjN	KDM4C KDM4E KDM4D KDM4B	1.86e-07	10	104	4	PF02375
Domain	JMJN	KDM4C KDM4E KDM4D KDM4B	1.86e-07	10	104	4	PS51183
Domain	JmjN	KDM4C KDM4E KDM4D KDM4B	1.86e-07	10	104	4	IPR003349
Domain	YD	NID2 TENM2 TENM1	1.66e-06	5	104	3	IPR006530
Domain	-	NID2 PON1 PON2 TENM2 TENM1	2.41e-06	39	104	5	2.120.10.30
Domain	6-blade_b-propeller_TolB-like	NID2 PON1 PON2 TENM2 TENM1	5.56e-06	46	104	5	IPR011042
Domain	JmjC	KDM4C KDM4E KDM4D KDM4B	8.85e-06	24	104	4	PF02373
Domain	JMJC	KDM4C KDM4E KDM4D KDM4B	2.89e-05	32	104	4	PS51184
Domain	JmjC_dom	KDM4C KDM4E KDM4D KDM4B	2.89e-05	32	104	4	IPR003347
Domain	JmjC	KDM4C KDM4E KDM4D KDM4B	3.28e-05	33	104	4	SM00558
Domain	Arylesterase	PON1 PON2	9.18e-05	3	104	2	PF01731
Domain	Arylesterase	PON1 PON2	9.18e-05	3	104	2	IPR002640
Domain	Galactose-bd-like	PCSK2 LAMA5 CUL9 PTPRU CNTNAP5	1.80e-04	94	104	5	IPR008979
Domain	Tox-GHH_dom	TENM2 TENM1	1.83e-04	4	104	2	IPR028916
Domain	Tox-GHH	TENM2 TENM1	1.83e-04	4	104	2	PF15636
Domain	Ten_N	TENM2 TENM1	1.83e-04	4	104	2	IPR009471
Domain	Ten_N	TENM2 TENM1	1.83e-04	4	104	2	PF06484
Domain	TENEURIN_N	TENM2 TENM1	1.83e-04	4	104	2	PS51361
Domain	Quino_amine_DH_bsu	NID2 TENM2 NBAS	2.39e-04	22	104	3	IPR011044
Domain	EPHD	JADE3 KDM4C KDM4B	2.39e-04	22	104	3	PS51805
Domain	TUDOR	KDM4C LBR KDM4B	4.45e-04	27	104	3	SM00333
Domain	Tudor	KDM4C LBR KDM4B	6.10e-04	30	104	3	IPR002999
Domain	FA_desaturase_dom	SCD FADS2	8.41e-04	8	104	2	IPR005804
Domain	FA_desaturase	SCD FADS2	8.41e-04	8	104	2	PF00487
Pathway	REACTOME_HDMS_DEMETHYLATE_HISTONES	KDM4C KDM4E KDM4D ARID5B KDM4B	3.49e-07	29	73	5	MM14934
Pubmed	Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family.	KDM4C KDM4E KDM4D KDM4B	4.39e-10	5	108	4	21914792
Pubmed	Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells.	KDM4C KDM4E KDM4D KDM4B	4.39e-10	5	108	4	16738407
Pubmed	Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins.	KDM4C KDM4E KDM4D KDM4B	2.85e-08	11	108	4	19144645
Pubmed	Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.	KDM4C KDM4E KDM4D KDM4B	5.05e-07	21	108	4	27626377
Pubmed	Identification and characterization of JMJD2 family genes in silico.	KDM4C KDM4D KDM4B	5.78e-07	6	108	3	15138608
Pubmed	Conduct disorder and ADHD: evaluation of conduct problems as a categorical and quantitative trait in the international multicentre ADHD genetics study.	PITRM1 PTPRU KDM4D RBFOX1	8.15e-06	41	108	4	18951430
Pubmed	Shotgun sequencing of the human transcriptome with ORF expressed sequence tags.	SZT2 ARHGAP26 TENM2 MSTO1 PEBP4 ADAMTS12 TENM1 CATSPERB IGSF9B KDM4B	9.01e-06	552	108	10	10737800
Pubmed	Interaction mapping of endoplasmic reticulum ubiquitin ligases identifies modulators of innate immune signalling.	EXOSC10 HYOU1 PON2 DIS3 SCD HS2ST1 FADS2	9.19e-06	235	108	7	32614325
Pubmed	Association of paraoxonase gene polymorphisms with sperm parameters.	PON1 PON2	9.55e-06	2	108	2	21127310
Pubmed	Repressive histone methylation regulates cardiac myocyte cell cycle exit.	KDM4E KDM4D	9.55e-06	2	108	2	29800554
Pubmed	SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells.	SCD FADS2	9.55e-06	2	108	2	35547771
Pubmed	Paraoxonase genotype and carotid intima-media thickness in children with familial hypercholesterolemia.	PON1 PON2	9.55e-06	2	108	2	16926679
Pubmed	Normalization of gene expression using SYBR green qPCR: a case for paraoxonase 1 and 2 in Alzheimer's disease brains.	PON1 PON2	9.55e-06	2	108	2	21672555
Pubmed	Paraoxonase-1 suppresses experimental colitis via the inhibition of IFN-γ production from CD4 T cells.	PON1 PRKDC	9.55e-06	2	108	2	23772025
Pubmed	Divergent iron regulatory states contribute to heterogeneity in breast cancer aggressiveness.	PRKDC C5	9.55e-06	2	108	2	39262774
Pubmed	[A search for association between the polymorphic markers of PON1 and PON2 genes and diabetic nephropathy in patients with type I diabetes mellitus].	PON1 PON2	9.55e-06	2	108	2	16080611
Pubmed	Reduced female fertility due to sequestration of RNA Pol II by pervasive transcription in exosome RNase-depleted oocytes.	EXOSC10 DIS3	9.55e-06	2	108	2	37831603
Pubmed	Lack of association of PON polymorphisms with sporadic ALS in an Italian population.	PON1 PON2	9.55e-06	2	108	2	20381198
Pubmed	Association of PON1 and PON2 polymorphisms with PON1 activity and significant coronary stenosis in a Tunisian population.	PON1 PON2	9.55e-06	2	108	2	23053877
Pubmed	High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival.	MAPK14 PRKDC	9.55e-06	2	108	2	31513357
Pubmed	Genetic variants of the paraoxonases (PON1 and PON2) in the Chilean population.	PON1 PON2	9.55e-06	2	108	2	15359538
Pubmed	Increased macrophage cholesterol biosynthesis and decreased cellular paraoxonase 2 (PON2) expression in Delta6-desaturase knockout (6-DS KO) mice: beneficial effects of arachidonic acid.	PON2 FADS2	9.55e-06	2	108	2	20042190
Pubmed	Circulating Fibroblast Growth Factor-23 Level and Paraoxonase-1 Lactonase Activity in Chronic Hemodialysis Patients: Their Impact on the Incidence of Native AV Fistula Thrombosis.	PON1 FGF23	9.55e-06	2	108	2	27805900
Pubmed	Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese.	PON1 PON2	9.55e-06	2	108	2	12955589
Pubmed	Oxidative stress-related genes in type 2 diabetes: association analysis and their clinical impact.	PON1 PON2	9.55e-06	2	108	2	25991559
Pubmed	Incompatibility in cell adhesion constitutes a barrier to interspecies chimerism.	PRKDC C5	9.55e-06	2	108	2	39181131
Pubmed	[Relationship between paraoxonase 1 55 Met/Leu, paraoxonase 2 148 Ala/Gly genetic polymorphisms and coronary artery disease].	PON1 PON2	9.55e-06	2	108	2	16767666
Pubmed	Isolation of slow-cycling cancer cells from lung patient-derived xenograft using carboxyfluorescein-succinimidyl ester retention-mediated cell sorting.	PRKDC C5	9.55e-06	2	108	2	36924504
Pubmed	SMURF1-mediated ubiquitination of ARHGAP26 promotes ovarian cancer cell invasion and migration.	ARHGAP26 SMURF1	9.55e-06	2	108	2	31004081
Pubmed	GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.	GATA2 MAPK14	9.55e-06	2	108	2	27545880
Pubmed	Human tissue distribution of paraoxonases 1 and 2 mRNA.	PON1 PON2	9.55e-06	2	108	2	20503442
Pubmed	Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes.	PON1 PON2	9.55e-06	2	108	2	11918623
Pubmed	Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence.	PON1 PON2	9.55e-06	2	108	2	9714608
Pubmed	Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models.	PRKDC C5	9.55e-06	2	108	2	39047119
Pubmed	Paraoxonase, a cardioprotective enzyme: continuing issues.	PON1 PON2	9.55e-06	2	108	2	15166781
Pubmed	[Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction].	PON1 PON2	9.55e-06	2	108	2	18361900
Pubmed	Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population.	PON1 PON2	9.55e-06	2	108	2	17309646
Pubmed	Pregranulosa cell-derived FGF23 protects oocytes from premature apoptosis during primordial follicle formation by inhibiting p38 MAPK in mice.	FGF23 MAPK14	9.55e-06	2	108	2	37142227
Pubmed	Kdm4d mutant mice show impaired sperm motility and subfertility.	KDM4E KDM4D	9.55e-06	2	108	2	39034148
Pubmed	Association of paraoxonase polymorphisms with carotid artery atherosclerosis in essential hypertension patients.	PON1 PON2	9.55e-06	2	108	2	24301778
Pubmed	Paraoxonase 1 and 2 gene variants and the ischemic stroke risk in Gran Canaria population: an association study and meta-analysis.	PON1 PON2	9.55e-06	2	108	2	26978533
Pubmed	Expression of SCD and FADS2 Is Lower in the Necrotic Core and Growing Tumor Area than in the Peritumoral Area of Glioblastoma Multiforme.	SCD FADS2	9.55e-06	2	108	2	32392704
Pubmed	Paraoxonase gene polymorphism and the risk for Alzheimer's disease in the polish population.	PON1 PON2	9.55e-06	2	108	2	21757906
Pubmed	Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.	KDM4E KDM4D	9.55e-06	2	108	2	32094404
Pubmed	Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan.	PON1 PON2	9.55e-06	2	108	2	19371607
Pubmed	Distinct and combinatorial functions of Jmjd2b/Kdm4b and Jmjd2c/Kdm4c in mouse embryonic stem cell identity.	KDM4C KDM4B	9.55e-06	2	108	2	24361252
Pubmed	Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study.	PON1 PON2	9.55e-06	2	108	2	12454802
Pubmed	Association of paraoxonase gene polymorphisms with diabetic nephropathy and retinopathy.	PON1 PON2	9.55e-06	2	108	2	24100645
Pubmed	Histone Demethylase JMJD2D Interacts With β-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.	KDM4E KDM4D	9.55e-06	2	108	2	30472235
Pubmed	Induction of OTUD1 by RNA viruses potently inhibits innate immune responses by promoting degradation of the MAVS/TRAF3/TRAF6 signalosome.	OTUD1 SMURF1	9.55e-06	2	108	2	29734366
Pubmed	FADS2 confers SCD1 inhibition resistance to cancer cells by modulating the ER stress response.	SCD FADS2	9.55e-06	2	108	2	38849435
Pubmed	Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma.	PRKDC C5	9.55e-06	2	108	2	37057874
Pubmed	Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer.	PON1 PON2	9.55e-06	2	108	2	20099504
Pubmed	p38 links RAS to GATA2.	GATA2 MAPK14	9.55e-06	2	108	2	25092790
Pubmed	The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study.	PON1 PON2	9.55e-06	2	108	2	19939821
Pubmed	RNA-regulatory exosome complex confers cellular survival to promote erythropoiesis.	EXOSC10 DIS3	9.55e-06	2	108	2	34059908
Pubmed	Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies.	PON1 PON2	9.55e-06	2	108	2	21146823
Pubmed	Detecting the polymorphisms of paraoxonase (PON) cluster in Chinese Han population based on a rapid method.	PON1 PON2	9.55e-06	2	108	2	16185677
Pubmed	Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications.	PON1 PON2	9.55e-06	2	108	2	12442067
Pubmed	Genetic variations of the paraoxonase gene in patients with coronary artery disease.	PON1 PON2	9.55e-06	2	108	2	11676977
Pubmed	Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.	PRKDC C5	9.55e-06	2	108	2	31543464
Pubmed	Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.	KDM4D KDM4B	9.55e-06	2	108	2	27630312
Pubmed	Polymorphisms of the paraoxonase gene and risk of preterm delivery.	PON1 PON2	9.55e-06	2	108	2	15232408
Pubmed	Paraoxonase gene polymorphisms and sporadic ALS.	PON1 PON2	9.55e-06	2	108	2	16822965
Pubmed	Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies.	PON1 PON2	9.55e-06	2	108	2	15001326
Pubmed	Polymorphisms of pon1 and pon2 genes in hemodialyzed patients.	PON1 PON2	9.55e-06	2	108	2	21620813
Pubmed	Associations between genetic polymorphisms of paraoxonase genes and coronary artery disease in a Taiwanese population.	PON1 PON2	9.55e-06	2	108	2	23742759
Pubmed	The Lhs1/GRP170 chaperones facilitate the endoplasmic reticulum-associated degradation of the epithelial sodium channel.	HYOU1 SCNN1A	9.55e-06	2	108	2	23645669
Pubmed	Paraoxonase gene polymorphisms and stroke severity.	PON1 PON2	9.55e-06	2	108	2	19930448
Pubmed	Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.	KDM4E KDM4D	9.55e-06	2	108	2	35027670
Pubmed	Embryonic development following somatic cell nuclear transfer impeded by persisting histone methylation.	KDM4E KDM4D	9.55e-06	2	108	2	25417163
Pubmed	Paraoxonase gene polymorphism in south-western Korean population.	PON1 PON2	9.55e-06	2	108	2	19654933
Pubmed	The paraoxonase gene polymorphism in stroke patients and lipid profile.	PON1 PON2	9.55e-06	2	108	2	17854416
Pubmed	Polymorphisms of paraoxonase 1 and 2 genes and the risk of multiple sclerosis in the Polish population.	PON1 PON2	9.55e-06	2	108	2	23487294
Pubmed	Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency.	PRKDC C5	9.55e-06	2	108	2	34702956
Pubmed	An in vivo neuroimmune organoid model to study human microglia phenotypes.	PRKDC C5	9.55e-06	2	108	2	37172564
Pubmed	Paraoxonase (PON)1 192R allele carriage is associated with reduced risk of inflammatory bowel disease.	PON1 PON2	9.55e-06	2	108	2	17436100
Pubmed	A dual-strategy expression screen for candidate connectivity labels in the developing thalamus.	PTPRU TENM2 SEMA6D TENM1 IGSF9B	9.89e-06	91	108	5	28558017
Pubmed	Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases.	KDM4C KDM4D KDM4B	1.03e-05	14	108	3	16603238
Pubmed	A Human Tyrosine Phosphatase Interactome Mapped by Proteomic Profiling.	EXOSC10 HYOU1 PITRM1 ARHGAP26 PON2 PTPRU DIS3 IGF2BP2 MAPK14 PIP5K1A PRKDC PIPSL VCPIP1	1.07e-05	974	108	13	28675297
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	RASA1 ATXN7L1 SMURF1 PON2 CHD2 PTPRB FAM168A TBC1D22A HS2ST1 ARID5B SCNN1A DIP2C PIP5K1A IGSF9B LRBA KDM4B	1.45e-05	1489	108	16	28611215
Pubmed	Identification of Jmjd3 as an Essential Epigenetic Regulator of Hox Gene Temporal Collinear Activation for Body Axial Patterning in Mice.	KDM4C KDM4E KDM4D KDM4B	1.67e-05	49	108	4	34368113
Pubmed	Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes--an 8-year prospective cohort analysis of 1297 patients.	PON1 PON2 SCNN1A C5	2.47e-05	54	108	4	20536507
Pubmed	Paraoxonase and atherosclerosis-related cardiovascular diseases.	PON1 PON2	2.86e-05	3	108	2	27771368
Pubmed	Association of fatty acid desaturase gene polymorphisms with blood lipid essential fatty acids and perinatal depression among Canadian women: a pilot study.	SCD FADS2	2.86e-05	3	108	2	20395685
Pubmed	[Study of the association between paraoxonase1 55 Met/Leu, paraoxonase2 148 Ala/Gly and manganese superoxide dismutase (MnSOD) 9 Ala/Val genetic polymorphisms and coronary heart disease].	PON1 PON2	2.86e-05	3	108	2	17299970
Pubmed	[Paraoxonase: The Universal Factor of Antioxidant Defense in Human Body].	PON1 PON2	2.86e-05	3	108	2	29308836
Pubmed	Inflammation, infection, cancer and all that…the role of paraoxonases.	PON1 PON2	2.86e-05	3	108	2	25038992
Pubmed	Ocular distribution of antioxidant enzyme paraoxonase & its alteration in cataractous lens & diabetic retina.	PON1 PON2	2.86e-05	3	108	2	28862184
Pubmed	Association Between Paraoxonase Gene Polymorphisms and Intracerebral Hemorrhage in a Korean Population.	PON1 PON2	2.86e-05	3	108	2	26227792
Pubmed	The three-gene paraoxonase family: physiologic roles, actions and regulation.	PON1 PON2	2.86e-05	3	108	2	20934178
Pubmed	Comparative expression analysis reveals differences in the regulation of intestinal paraoxonase family members.	PON1 PON2	2.86e-05	3	108	2	19401157
Pubmed	Paraoxonase gene polymorphisms and haplotype analysis in a stroke population.	PON1 PON2	2.86e-05	3	108	2	16551349
Pubmed	Genetic variation in lipid desaturases and its impact on the development of human disease.	SCD FADS2	2.86e-05	3	108	2	20565855
Pubmed	Continuous reduction of plasma paraoxonase activity with increasing dialysis vintage in hemodialysis patients.	PON1 PON2	2.86e-05	3	108	2	21118365
Pubmed	Effects of PON polymorphisms and haplotypes on molecular phenotype in Mexican-American mothers and children.	PON1 PON2	2.86e-05	3	108	2	20839225
Pubmed	Regulation of desaturase expression in HL60 cells.	SCD FADS2	2.86e-05	3	108	2	17852835
Pubmed	Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women.	PON1 PON2	2.86e-05	3	108	2	16117861
Pubmed	Comparative integromics on JMJD2A, JMJD2B and JMJD2C: preferential expression of JMJD2C in undifferentiated ES cells.	KDM4C KDM4B	2.86e-05	3	108	2	17611647
Pubmed	The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.	KDM4E KDM4D	2.86e-05	3	108	2	21555854
GeneFamily	PHD finger proteins\|Lysine demethylases	KDM4C KDM4E KDM4D KDM4B	2.58e-06	24	74	4	485
GeneFamily	Paraoxonases	PON1 PON2	4.94e-05	3	74	2	463
GeneFamily	Fatty acid desaturases	SCD FADS2	4.55e-04	8	74	2	553
GeneFamily	Tudor domain containing	KDM4C LBR KDM4B	4.63e-04	37	74	3	780
GeneFamily	Exosome complex	EXOSC10 DIS3	1.06e-03	12	74	2	817
GeneFamily	OTU domain containing	OTUD1 VCPIP1	2.16e-03	17	74	2	669
GeneFamily	Heat shock 70kDa proteins	HYOU1 HSPA12A	2.16e-03	17	74	2	583
GeneFamily	Protein tyrosine phosphatases, receptor type	PTPRU PTPRB	3.30e-03	21	74	2	813
ToppCell	Tracheal-10x5prime-Stromal-Schwann\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	PCSK2 GLDN FRMD1 HSPA12A SEMA6D SCD RASSF4	5.14e-07	196	108	7	b6226163d9fc93ecfff2115bb74408303a000490
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	CACNA1F NID2 NLGN1 PTPRU SCNN1A MYRF PHLDB2	5.70e-07	199	108	7	d43c605a4ff221cf78d91678c15d2ad20f831c7f
ToppCell	COVID-19-Epithelial_cells-AT2\|COVID-19 / group, cell type (main and fine annotations)	PCSK2 NLGN1 TTC6 PEBP4 SCD SCNN1A	5.84e-06	184	108	6	369b82f793deab672204558ae4e112cfa5aa9ccc
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L4_RORB_CACNG5\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	GLDN NLGN1 KCNIP1 TENM2 CNTNAP5 TENM1	5.84e-06	184	108	6	658f2e522055e88c92bc482a845c40f8f5f1a8e3
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1-D122\|Adult / Lineage, Cell type, age group and donor	LAMA5 KCNIP1 SEMA6D SCNN1A MYRF PHLDB2	5.84e-06	184	108	6	561592edc3083fad41b91811151b442207c65dd9
ToppCell	Control-Epithelial-ATI\|World / Disease state, Lineage and Cell class	LAMA5 KCNIP1 PEBP4 SCNN1A MYRF PHLDB2	6.02e-06	185	108	6	0563d5042bb96ecce8446fbf26d05ef7a45e23c5
ToppCell	Control-Epithelial-ATI\|Control / Disease state, Lineage and Cell class	LAMA5 KCNIP1 PEBP4 SCNN1A MYRF PHLDB2	6.40e-06	187	108	6	fdd1c57b61ca9392ac27661a82729f37593df63c
ToppCell	E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SZT2 KDM4C SMURF1 MSTO1 PTPRB SEMA6D	6.40e-06	187	108	6	3699d5e71d779da922920aa3160895db187bf81b
ToppCell	E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1-CAP1_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SZT2 KDM4C SMURF1 MSTO1 PTPRB SEMA6D	6.40e-06	187	108	6	033ba52c0c2f9978784947098fa697368ae44834
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1\|Adult / Lineage, Cell type, age group and donor	LAMA5 KCNIP1 SEMA6D SCNN1A MYRF PHLDB2	6.40e-06	187	108	6	77f78aec946bc6bd85c29aee9ca978ce49f853a3
ToppCell	CD8+_Memory_T_cell-CV-7\|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster	HYOU1 LBR PARP14 NBAS PRKDC LRBA	7.23e-06	191	108	6	9454f642c3621370fa23640b631301346b300950
ToppCell	COVID-19-lung-AT2\|lung / Disease (COVID-19 only), tissue and cell type	PCSK2 NLGN1 TTC6 PEBP4 SCD SCNN1A	7.23e-06	191	108	6	276455a64c2c3503d5048615762eb2ee37f0ac70
ToppCell	Bronchial-NucSeq-Epithelial-Epi_alveolar-AT1\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LAMA5 KCNIP1 SEMA6D SCNN1A MYRF PHLDB2	8.14e-06	195	108	6	a71ba5e4043e2d35a45a2c60a96b087e31832345
ToppCell	Tracheal-10x5prime-Stromal-Schwann-Schwann_nonmyelinating\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	PCSK2 HSPA12A SEMA6D SCD TENM1 RASSF4	8.62e-06	197	108	6	e239caae24f40564a24ad909754f5436f767ccdb
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	KDM4C ARHGAP26 NBAS TBC1D22A DIP2C LRBA	9.13e-06	199	108	6	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / Treatment groups by lineage, cell group, cell type	CACNA1F PTPRU SCNN1A C5 MYRF PHLDB2	9.40e-06	200	108	6	2dadf317a42a7e27cc1fac74f91b806c93a57108
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	CACNA1F NID2 PTPRU SCNN1A MYRF PHLDB2	9.40e-06	200	108	6	8683445ad5b70748c4a1f12eb77d47623085147e
ToppCell	Biopsy_Control_(H.)-Epithelial-AT1\|Biopsy_Control_(H.) / Sample group, Lineage and Cell type	LAMA5 KCNIP1 SEMA6D SCNN1A MYRF PHLDB2	9.40e-06	200	108	6	3a9633f5913f12b6865fc777c84f3f3ba795a78d
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NLGN1 TTC6 SCNN1A C5 MYRF	1.64e-05	130	108	5	6434d9106ccb38786dad36fab80163dfc07b6eb7
ToppCell	facs-Limb_Muscle-forelimb_and_hindlimb-18m-Endothelial\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF6 GLDN PEBP4 TNNI3K PTPRB	2.11e-05	137	108	5	b831d917f5073ccff158662adb281d34f023126a
ToppCell	facs-Limb_Muscle-forelimb_and_hindlimb-18m-Endothelial-nan\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF6 GLDN PEBP4 TNNI3K PTPRB	2.11e-05	137	108	5	cf3e928d9a7a7349840bb87475a42a07f65b94f0
ToppCell	facs-Limb_Muscle-forelimb_and_hindlimb-18m-Endothelial-endothelial_cell\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF6 GLDN PEBP4 TNNI3K PTPRB	2.11e-05	137	108	5	5d82d6c7eef4ec7a7fae60e37fb956488314987e
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NID2 PON1 PON2 RBFOX1 IGSF9B	2.96e-05	147	108	5	989a48bda98fbff398985397a6b1189a4cbc80e7
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NID2 PON1 PON2 RBFOX1 IGSF9B	2.96e-05	147	108	5	f6681c849c4c06154548bd29a094f202d1c946c2
ToppCell	COVID-19-lung-Mesothelial\|lung / Disease (COVID-19 only), tissue and cell type	NLGN1 HSPA12A SEMA6D RBFOX1 MYRF	3.93e-05	156	108	5	e1f563869b3bf997eaa2e756e31b53db1a478903
ToppCell	PBMC-Severe-Myeloid-cDC-cDC-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	GLDN ZNF619 MS4A4A STS ZNF341	4.84e-05	163	108	5	ec8336b68c8369e27d507c04c827be07bb48a7f6
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	OTUD1 LAMA5 PARP14 STS PHLDB2	5.75e-05	169	108	5	665b958f4a720ca369a8a0abc7fbe8b6e13c8ce5
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	OTUD1 LAMA5 PARP14 STS PHLDB2	5.75e-05	169	108	5	6614c9851537e4c21b1e45ff0cc3bad07ef9d034
ToppCell	356C-Myeloid-Dendritic-cDC_activated\|Dendritic / Donor, Lineage, Cell class and subclass (all cells)	JADE3 GATA2 LAMA5 VASH2 RASSF4	5.91e-05	170	108	5	513d9036aa41d4d902da8baa66a66206abb6f3b0
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_6\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	CACNA1F CORO2A ARHGAP26 PLEKHN1 SCNN1A	6.25e-05	172	108	5	a9e13aa36087170dadca421ba9de588e5a1cf715
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L4-5_RORB_ASCL1\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	GLDN NLGN1 KCNIP1 TENM1 PHLDB2	6.42e-05	173	108	5	2e35bf2b5534a289d93a09faae660f665c131062
ToppCell	10x3'2.3-week_17-19-Neuro\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	PCSK2 NID2 KCNIP1 HSPA12A IGSF9B	6.78e-05	175	108	5	bbce8b1a160b414c0bf643c21c4e5e78fbccb7e1
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_6\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	CACNA1F CORO2A PLEKHN1 FCHO1 SCNN1A	6.78e-05	175	108	5	f3a68aeb79c4935006e17a5ff3445a8ec0e33f5f
ToppCell	10x3'2.3-week_17-19-Neuro-stroma-schwann_cells\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	PCSK2 NID2 KCNIP1 HSPA12A IGSF9B	6.78e-05	175	108	5	8b010220cdfb680ec839572f4933adfb85045ea6
ToppCell	10x3'2.3-week_17-19-Neuro-stroma\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	PCSK2 NID2 KCNIP1 HSPA12A IGSF9B	6.78e-05	175	108	5	0b579aeadcc06be83627391c0b01bd8605fdbdf3
ToppCell	AT1_cells-HP_01\|World / lung cells shred on cell class, cell subclass, sample id	LAMA5 STS SEMA6D MYRF PHLDB2	6.96e-05	176	108	5	458720776b0151cd55acc352d509599cb62f0ca8
ToppCell	CV-Severe-7\|CV / Virus stimulation, Condition and Cluster	HYOU1 PARP14 AGO3 SCD IGSF9B	6.96e-05	176	108	5	3de0c7d77210049e5616db21eed1490a17a5ec2d
ToppCell	CV-Severe-7\|Severe / Virus stimulation, Condition and Cluster	HYOU1 NBAS AGO3 SCD IGSF9B	7.15e-05	177	108	5	82fdd6185b368f54f03de389427cbe3071d21a99
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CACNA1F NLGN1 SCNN1A MYRF PHLDB2	7.95e-05	181	108	5	b45b11428d13950369347e051d4d517efb2bd4fd
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PON2 NLGN1 SCNN1A MYRF PHLDB2	8.37e-05	183	108	5	274483009b309289e4cb84beedf6806430db6ff6
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NLGN1 SCNN1A C5 MYRF PHLDB2	8.37e-05	183	108	5	ff6dde877659cde9daa3263db0932c9c9ef1adac
ToppCell	AT1-AT2_cells-Donor_02\|World / lung cells shred on cell class, cell subclass, sample id	LAMA5 TNNI3K SEMA6D MYRF PHLDB2	8.37e-05	183	108	5	6821dca076318115d360ff426eb1218cfe104063
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	LAMA5 KCNIP1 SCNN1A MYRF PHLDB2	8.59e-05	184	108	5	57c792e6e2fedba25d3350ffe649fd74750b579d
ToppCell	facs-Diaphragm-Limb_Muscle-18m-Lymphocytic-T_cell\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DCPS CORO2A ATXN7L1 FCHO1 PAQR7	8.59e-05	184	108	5	185b49630da61cbf45c0926d1b992943296d2a54
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Cortical_Thick_Ascending_Limb_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	SIM2 SEMA6D RBFOX1 SCNN1A LRBA	8.59e-05	184	108	5	e8238fe58f94b4f5700ab7f343fb06ea61e899a9
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	LAMA5 KCNIP1 SCNN1A MYRF PHLDB2	8.59e-05	184	108	5	d7bd0f0c607bade67c99e9fb3578a570298bf926
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1\|Children_(3_yrs) / Lineage, Cell type, age group and donor	LAMA5 KCNIP1 SEMA6D MYRF PHLDB2	8.81e-05	185	108	5	1c222f7285d6e3dae0354dc7e853ddc0ea55e63e
ToppCell	18-Distal-Epithelial-Neuroendocrine\|Distal / Age, Tissue, Lineage and Cell class	PCSK2 PON1 CFAP65 RBFOX1 SCNN1A	8.81e-05	185	108	5	f8fc7b12b4e18d23d84e95488be93c4352d325f3
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NLGN1 SCNN1A C5 MYRF PHLDB2	9.04e-05	186	108	5	4e94158db52df41d71e67b02b9895a358eebee0f
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NID2 NLGN1 SIM2 TENM1 DIP2C	9.04e-05	186	108	5	f0c8de4f6ae9047b9108a47a2af8c5f42bc103b0
ToppCell	droplet-Fat-SCAT-30m-Epithelial\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SZT2 PON1 TTC6 ZSWIM9 SLC25A35	9.27e-05	187	108	5	5fada3c5a58c1890029ccbfff2608b33f8cd2df7
ToppCell	3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Cycling_pre-Myeloid-2\|lymph-node_spleen / Manually curated celltypes from each tissue	ZNF619 MS4A4A MAPK14 FADS2 RASSF4	9.27e-05	187	108	5	3c10b8501226c69d71bcd99dc1c064a3c2154f87
ToppCell	droplet-Fat-SCAT-30m-Epithelial-nan\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SZT2 PON1 TTC6 ZSWIM9 SLC25A35	9.27e-05	187	108	5	766e808138fc2cd623c2e6d57fcb5c7378da0e03
ToppCell	droplet-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l30\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	NID2 NLGN1 ADAMTS12 ZSWIM9 RBFOX1	9.27e-05	187	108	5	8e8b147258982b359447add5027318f5b6d51963
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Degenerative_Descending_Thin_Limb_Cell_Type_3\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NID2 NLGN1 SIM2 TENM1 DIP2C	9.27e-05	187	108	5	c31130fc2f9f882944b2ba366a034a03f051c4b9
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NLGN1 SCNN1A C5 MYRF PHLDB2	9.27e-05	187	108	5	58d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCell	LPS_only-Epithelial_alveolar-AT_1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NLGN1 SCNN1A C5 MYRF PHLDB2	9.27e-05	187	108	5	ff26a533d310126521efe1d05cf8b9d32e524550
ToppCell	368C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)\|368C / Donor, Lineage, Cell class and subclass (all cells)	CHAF1B SMURF1 LAMA5 SCNN1A LRBA	9.27e-05	187	108	5	b827d9da7032bf051756ddf88352af922eb0f87b
ToppCell	droplet-Fat-SCAT-30m-Epithelial-epithelial_cell\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SZT2 PON1 TTC6 ZSWIM9 SLC25A35	9.27e-05	187	108	5	f49d06600060deeb2fc1b1da5b93496535f20104
ToppCell	368C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)-\|368C / Donor, Lineage, Cell class and subclass (all cells)	CHAF1B SMURF1 LAMA5 SCNN1A LRBA	9.27e-05	187	108	5	61c00604dda8b36a5c3eea6554e5601aa1b884f7
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NLGN1 SIM2 IGF2BP2 TENM1 DIP2C	9.50e-05	188	108	5	af740fa78542438fdff627ea1f74f4eee43316be
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SIM2 SEMA6D RBFOX1 SCNN1A LRBA	9.74e-05	189	108	5	f51cdc9a47371cab8ed9ae63a6f14da07ede446c
ToppCell	cellseq-Immune-Hematopoietic-Granulocytic-Neutrophil\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	LBR MAPK14 XPO6 TENM1 MMP8	9.74e-05	189	108	5	fedab592be1d6520325b8c1b659b0a4dc3f4fe4d
ToppCell	RV-15._Ventricular_Cardiomyocyte_III\|World / Chamber and Cluster_Paper	NLGN1 TENM2 RBFOX1 DIP2C PHLDB2	9.74e-05	189	108	5	0a82931b5f6c0a6427ca3edd5e2235ac49099d40
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1-D231\|Adult / Lineage, Cell type, age group and donor	LAMA5 KCNIP1 DIP2C MYRF PHLDB2	9.74e-05	189	108	5	5a04cb25f8f0447b2cecdb6c3695029281aca26d
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	PON2 SIM2 RBFOX1 ARID5B SCNN1A	9.99e-05	190	108	5	bf4511395fa97efd1c1cd17cc9bebb0271ee7f0e
ToppCell	(7)_Epithelial-D_(AT2)\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	PCSK2 PON2 PEBP4 SCD SCNN1A	9.99e-05	190	108	5	832d6d3ad14665e50623afe1b8586ccae1a97de5
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	PON2 SIM2 RBFOX1 ARID5B SCNN1A	9.99e-05	190	108	5	b6b8964b4910083499681b5fdf554e127b6a4c4e
ToppCell	Globus_pallidus-Neuronal\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	CELF6 TENM2 FCHO1 EFNA3 TENM1	9.99e-05	190	108	5	416de85d8841dac883faa6f5339b2fb461a09e82
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SIM2 SEMA6D RBFOX1 SCNN1A LRBA	9.99e-05	190	108	5	b94df372bc08de11585b2467dba8c8fffff5cd92
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PON2 TTC6 PEBP4 SCNN1A MYRF	1.02e-04	191	108	5	ca5669bd6f4a17471acae3eb229f845cc2e08efa
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-mesothelial_cell\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LAMA5 PLEKHN1 TENM2 RBFOX1 MYRF	1.05e-04	192	108	5	2f539653a20006bef814e6b4acd1023d6fdad5c6
ToppCell	Entopeduncular-Neuronal\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	CELF6 TENM2 CNTNAP5 RBFOX1 TENM1	1.05e-04	192	108	5	4c35e5c28a40b439044797ba1f06cb7c36b2a8de
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	ATXN7L1 NLGN1 TBC1D22A DIP2C LRBA	1.05e-04	192	108	5	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	RASA1 KDM4C ARHGAP26 FAM168A LRBA	1.07e-04	193	108	5	779276e775cb2492e8dd36436295a536084a6415
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NLGN1 IGF2BP2 SCNN1A DIP2C LRBA	1.07e-04	193	108	5	3866667dd221612589ae50f5c52f73a183a49ce6
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PCSK2 CHD2 PEBP4 SCNN1A CATSPERB	1.10e-04	194	108	5	97534c8bba895a7913665e03ae4e5c4a6ad71daf
ToppCell	normal_Lung-Epithelial_cells-AT1\|normal_Lung / Location, Cell class and cell subclass	LAMA5 PEBP4 SEMA6D SCNN1A MYRF	1.13e-04	195	108	5	569d1ebc5a5aa110a2430b096755ae35354040c4
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	KDM4C SMURF1 TBC1D22A DIP2C LRBA	1.16e-04	196	108	5	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	Epithelial_cells-AT1_cells\|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id	OTUD1 LAMA5 SEMA6D MYRF PHLDB2	1.16e-04	196	108	5	6c99d29162848161c1f166a032320f87a5d5a631
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-2M-Neuronal-midbrain/hindbrain_cells\|Organoid-2M / Sample Type, Dataset, Time_group, and Cell type.	PCSK2 TFAP2D GATA2 TENM2 TENM1	1.16e-04	196	108	5	0767581b69bc7e6334d580ca02ed1e831b7b55da
ToppCell	(7)_Epithelial-B_(AT2)\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	PCSK2 PEBP4 SCD SCNN1A C5	1.16e-04	196	108	5	345d4cc062b43bca9d506fbf23363469a9ba496f
ToppCell	severe-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	KDM4C GATA2 ARID5B TENM1 LRBA	1.18e-04	197	108	5	57ebd552f10d6278623b52a3d484d4b91ae1d028
ToppCell	Parenchymal-NucSeq-Epithelial-Epi_alveolar-AT1\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LAMA5 KCNIP1 SEMA6D MYRF PHLDB2	1.18e-04	197	108	5	8d5097898dd01cedb04cb694cb480c931e08462c
ToppCell	LPS_IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	CACNA1F NID2 PTPRU SCNN1A PHLDB2	1.21e-04	198	108	5	b598ab958e31f1e98bd06dc0097b58ac3a3f90a3
ToppCell	Control_saline-Epithelial_alveolar-AT_1\|Control_saline / Treatment groups by lineage, cell group, cell type	NID2 PON2 PTPRU SCNN1A PHLDB2	1.21e-04	198	108	5	9b161285df7a4e51618f3517cfc5b8221ba55786
ToppCell	ASK428-Epithelial-Type_1\|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq	OTUD1 LAMA5 SEMA6D MYRF PHLDB2	1.21e-04	198	108	5	0047a9ef7684230ac5179efea94461480e90bdaf
ToppCell	Tracheal-NucSeq-Stromal-Peri/Epineurial_\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NLGN1 TENM2 ADAMTS12 SEMA6D PHLDB2	1.24e-04	199	108	5	3835452e4848d7f7dd8651c17b746b271ef39688
ToppCell	Biopsy_IPF-Epithelial-Transitional_AT2\|Biopsy_IPF / Sample group, Lineage and Cell type	PCSK2 PON2 LAMA5 PEBP4 SCNN1A	1.24e-04	199	108	5	83ff8b7e472d1212324c05cc719b746d19e5e23b
ToppCell	Bronchial-10x5prime-Stromal-Peri/Epineurial_\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NLGN1 OMD TENM2 ADAMTS12 SEMA6D	1.24e-04	199	108	5	45c3b853900d8c3d5965117d904e3714100138bc
ToppCell	Tracheal-NucSeq-Stromal-Peri/Epineurial_-NAF_epineurial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NLGN1 TENM2 ADAMTS12 SEMA6D PHLDB2	1.24e-04	199	108	5	9c2db0bb94cba71a3cc1827844da090e213e0258
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PCSK2 PEBP4 SCD FADS2 C5	1.24e-04	199	108	5	2dc33804f6691d7c9682e6c9b885e945fb97fc36
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	CACNA1F NID2 PTPRU SCNN1A PHLDB2	1.27e-04	200	108	5	ddfb1f006365bf16203ee49f20200f68220cc288
ToppCell	390C-Lymphocytic-NK_cells-NK_cell_A2\|390C / Donor, Lineage, Cell class and subclass (all cells)	MARS2 ZNF619 MTRF1 KDM4B	1.54e-04	111	108	4	dfbdeadad321392d359e6fb7112b28b043a4b874
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_intermediate-B_activate-7\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	JADE3 FGF23 KDM4D DIP2C	2.51e-04	126	108	4	518a6e4919981b556ce6b451a91270dba976bc75
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Slc17a6-Excitatory_Neuron.Slc17a6.Oprk1_(Claustrum_cortex)\|Striatum / BrainAtlas - Mouse McCarroll V32	TFAP2D PTPRU CNTNAP5 IGSF9B	2.66e-04	128	108	4	7e3f5cea91af005f08d8e9340fb8630bf1c887c3
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Slc17a6\|Striatum / BrainAtlas - Mouse McCarroll V32	TFAP2D PTPRU CNTNAP5 IGSF9B	2.66e-04	128	108	4	a876303c852db2af9418d1a1711d7c950805018a
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Slc17a6-Excitatory_Neuron.Slc17a6.Oprk1_(Claustrum_cortex)-\|Striatum / BrainAtlas - Mouse McCarroll V32	TFAP2D PTPRU CNTNAP5 IGSF9B	2.66e-04	128	108	4	388062f840fd04cb8087f27a9a78e7a192920e3e
ToppCell	E18.5-samps-Epithelial-Alveolar_epithelial-AT1\|E18.5-samps / Age Group, Lineage, Cell class and subclass	PANX3 PEBP4 SCNN1A MYRF	2.83e-04	130	108	4	eb16a8f8f62add5fdd29c78d4608b6d1a06767f1
ToppCell	LPS-IL1RA-Endothelial-Epi-like-Alv_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PCSK2 KCNIP1 EFNA3 DCLRE1A	3.55e-04	138	108	4	5f8ac8f67e34a7cf560099208e6884102532391e
Drug	Drofenine hydrochloride [548-66-3]; Up 200; 11.4uM; PC3; HT_HG-U133A	CDHR2 ATXN7L1 ARHGAP26 SMURF1 STS HS2ST1 DIP2C KDM4B	3.83e-06	196	106	8	7129_UP
Drug	16-phenyl tetranor Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A	SZT2 FRMD1 DIS3 HSPA12A MAPK14 SEMA6D TBC1D22A C5	3.98e-06	197	106	8	7505_UP
Drug	methyl phenyl phosphate	PON1 PON2	2.15e-05	2	106	2	CID000301276
Drug	BcdA	PON1 PON2	2.15e-05	2	106	2	CID000065116
Drug	5,6,7,8-tetrahydroxy-4-oxooctanal	PON1 PON2	2.15e-05	2	106	2	ctd:C550995
Drug	NSC 2885	PON1 PON2	2.15e-05	2	106	2	CID000070425
Drug	0317956-0000 [391210-11-0]; Down 200; 10uM; MCF7; HT_HG-U133A	SZT2 CDHR2 SIM2 OMD MAPK14 STS KDM4B	3.06e-05	190	106	7	3966_DN
Drug	Thioperamide maleate [106243-16-7]; Up 200; 9.8uM; MCF7; HT_HG-U133A	SZT2 CDHR2 KDM4C FRMD1 STS FAM168A VCPIP1	3.17e-05	191	106	7	3392_UP
Drug	Pyrantel tartrate [33401-94-4]; Up 200; 11.2uM; PC3; HT_HG-U133A	SZT2 KDM4C FGF23 SEMA6D TBC1D22A RBFOX1 KDM4B	3.74e-05	196	106	7	5088_UP
Drug	Tranexamic acid [1197-18-8]; Down 200; 25.4uM; MCF7; HT_HG-U133A	SMURF1 PTPRU GPR107 TMEM62 FAM168A C5 KDM4B	3.74e-05	196	106	7	6238_DN
Drug	3-nitropropionic acid; Up 200; 10uM; MCF7; HT_HG-U133A	ADAM18 FRMD1 ADAMTS12 SEMA6D SCNN1A TENM1 MMP8	3.86e-05	197	106	7	6367_UP
Drug	genistein; Down 200; 10uM; MCF7; HT_HG-U133A	GATA2 PTPRU GPR107 TBC1D22A VASH2 DCLRE1A C5	3.86e-05	197	106	7	6952_DN
Drug	Alprostadil [745-65-3]; Down 200; 11.2uM; PC3; HT_HG-U133A	CDHR2 KDM4C NLGN1 PTPRB STS RBFOX1 MYRF	3.99e-05	198	106	7	4099_DN
Drug	16-phenyl tetranor Prostaglandin E2; Down 200; 10uM; MCF7; HT_HG-U133A	ADAM18 CHST8 EFNA3 TBC1D22A FADS2 KDM4B VCPIP1	3.99e-05	198	106	7	7505_DN
Drug	PHA-00767505E [723337-45-9]; Up 200; 10uM; MCF7; HT_HG-U133A	PON1 KCNIP1 FRMD1 FGF23 MAPK14 VASH2 KDM4B	3.99e-05	198	106	7	6550_UP
Drug	Diclofenac sodium [15307-79-6]; Up 200; 12.6uM; PC3; HT_HG-U133A	CDHR2 ARHGAP26 SMURF1 PON1 STS TBC1D22A TENM1	3.99e-05	198	106	7	5861_UP
Drug	Pirlindole mesylate [60762-57-4]; Up 200; 12.4uM; MCF7; HT_HG-U133A	CDHR2 OMD FRMD1 DIS3 EFNA3 PTPRB HS2ST1	4.12e-05	199	106	7	6519_UP
Drug	ketene	PON1 PON2 MMP8	6.36e-05	17	106	3	CID000010038
Drug	d22-29	PON1 PON2	6.42e-05	3	106	2	CID000077709
Drug	I2-15	SCD FADS2	6.42e-05	3	106	2	CID000013388
Drug	O,O-diethyl O-(4-carbamoylphenyl)phosphate	PON1 PON2	6.42e-05	3	106	2	CID000151413
Drug	1-acyl-2-(12-((7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)dodecanoyl)phosphatidylcholine	SCD FADS2	6.42e-05	3	106	2	ctd:C078632
Drug	xylenol orange	PON1 PON2 RBFOX1	1.06e-04	20	106	3	CID000073041
Drug	o-nitrophenylbutyrate	PON1 PON2	1.28e-04	4	106	2	CID000075600
Drug	phenyl acetate	PON1 PON2	1.28e-04	4	106	2	ctd:C570634
Drug	Tetriso	PON1 PON2	1.28e-04	4	106	2	CID000161384
Drug	5-hydroxyeicosatetraenoic acid lactone	PON1 PON2	1.28e-04	4	106	2	ctd:C047651
Drug	9-hexadecenal	SCD FADS2	1.28e-04	4	106	2	CID000092066
Drug	4-hydroxyphenyl acetate	PON1 PON2	1.28e-04	4	106	2	CID000096009
Drug	coroxon	PON1 PON2	1.28e-04	4	106	2	CID000009453
Drug	methyl phenylphosphonate	PON1 PON2	1.28e-04	4	106	2	CID000024913
Drug	AC1L9LQQ	LBR SCD FADS2 C5	1.45e-04	57	106	4	CID000448224
Drug	3,5,6-trichloro-2-pyridinol	PON1 PON2 MAPK14	1.62e-04	23	106	3	CID000023017
Drug	C16:1n-7	PON1 PIGV SCD FADS2	1.66e-04	59	106	4	CID000004668
Drug	trinexapac-ethyl	PON1 PON2 C5	2.09e-04	25	106	3	CID000092421
Drug	alamos	PON1 PON2 LBR	2.09e-04	25	106	3	CID000079914
Drug	AC1Q6SGD	PON1 PON2	2.13e-04	5	106	2	CID000016775
Drug	AC1L1V7J	PON1 PON2	2.13e-04	5	106	2	CID000036158
Drug	phenylacetic acid	PON1 PON2	2.13e-04	5	106	2	ctd:C025136
Drug	1-penten-3-ol	SCD FADS2	2.13e-04	5	106	2	CID000012020
Drug	vamidothion	PON1 PON2	2.13e-04	5	106	2	CID000560193
Drug	diethylaminoethanethiol	PON1 PON2	2.13e-04	5	106	2	CID000016031
Drug	fensulfothion	PON1 PON2	2.13e-04	5	106	2	CID000008292
Drug	methyl sterculate	SCD FADS2	2.13e-04	5	106	2	CID000115261
Drug	16-methylprogesterone	SCD FADS2	2.13e-04	5	106	2	CID000134874
Drug	1,5,9-triazacyclododecane	PON1 PON2	2.13e-04	5	106	2	CID000470778
Drug	crufomate	PON1 PON2	2.13e-04	5	106	2	CID000009300
Drug	GSK-3beta Inhibitor VIII; Down 200; 10uM; PC3; HT_HG-U133A	NID2 MTRF1 TMEM62 EFNA3 STS VASH2	2.74e-04	191	106	6	7070_DN
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A	KDM4C HSPA12A RBFOX1 VASH2 FADS2 IQCK	2.90e-04	193	106	6	1464_DN
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; HL60; HT_HG-U133A	CDHR2 ARHGAP26 OMD TBC1D22A RBFOX1 IQCK	2.90e-04	193	106	6	2675_DN
Drug	Alprenolol hydrochloride [13707-88-5]; Up 200; 14uM; MCF7; HT_HG-U133A	CDHR2 KCNIP1 CHST8 EFNA3 STS FADS2	2.90e-04	193	106	6	6789_UP
Drug	(-) -Levobunolol hydrochloride [27912-14-7]; Down 200; 12.2uM; HL60; HT_HG-U133A	CDHR2 SMURF1 OMD STS TBC1D22A RBFOX1	2.98e-04	194	106	6	3015_DN
Drug	LY 294002; Up 200; 10uM; PC3; HT_HG-U133A	SZT2 CUL9 SIM2 FGF23 FADS2 MYRF	2.98e-04	194	106	6	1239_UP
Drug	5194442; Up 200; 20uM; PC3; HT_HG-U133A	KDM4C ARHGAP26 PTPRU KDM4D EFNA3 TBC1D22A	2.98e-04	194	106	6	6553_UP
Drug	Roxithromycin [80214-83-1]; Down 200; 4.8uM; PC3; HT_HG-U133A	GATA2 MTRF1 HSPA12A MAPK14 STS C5	2.98e-04	194	106	6	4192_DN
Drug	Isradipine [75695-93-1]; Down 200; 10.8uM; PC3; HT_HG-U133A	GPR107 KDM4D TBC1D22A FADS2 DCLRE1A C5	2.98e-04	194	106	6	6347_DN
Drug	Karakoline [39089-30-0]; Down 200; 10.6uM; MCF7; HT_HG-U133A	RASA1 DIS3 CHST8 FGF23 EFNA3 TBC1D22A	3.06e-04	195	106	6	6059_DN
Drug	S(+)-Terguride [37686-84-3]; Up 200; 11.8uM; PC3; HT_HG-U133A	CDHR2 CHST8 EFNA3 FADS2 MYRF KDM4B	3.06e-04	195	106	6	6299_UP
Drug	haloperidol; Down 200; 10uM; HL60; HT_HG-U133A	ARHGAP26 GATA2 SMURF1 NLGN1 STS RBFOX1	3.06e-04	195	106	6	2663_DN
Drug	Homosalate [118-56-9]; Up 200; 15.2uM; MCF7; HT_HG-U133A	ARHGAP26 PON1 FRMD1 AGO3 RBFOX1 SCNN1A	3.06e-04	195	106	6	4355_UP
Drug	Amidopyrine [58-15-1]; Down 200; 17.2uM; PC3; HT_HG-U133A	KDM4C GATA2 SMURF1 GPR107 MAPK14 IQCK	3.06e-04	195	106	6	4481_DN
Drug	Triflusal [322-79-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A	PTPRU FCHO1 GPR107 TMEM62 DCLRE1A KDM4B	3.06e-04	195	106	6	7451_DN
Drug	Amiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; MCF7; HT_HG-U133A	SZT2 ATXN7L1 NLGN1 CHST8 SCNN1A KDM4B	3.15e-04	196	106	6	5253_UP
Drug	estradiol, USP; Down 200; 0.1uM; MCF7; HT_HG-U133A	GATA2 SMURF1 KCNIP1 FRMD1 EFNA3 VASH2	3.15e-04	196	106	6	5568_DN
Drug	Acemetacin [53164-05-9]; Up 200; 9.6uM; PC3; HT_HG-U133A	KDM4C PTPRU EFNA3 STS TBC1D22A RBFOX1	3.15e-04	196	106	6	6361_UP
Drug	Foliosidine [2520-38-9]; Down 200; 13uM; MCF7; HT_HG-U133A	KDM4C SIM2 GPR107 EFNA3 SEMA6D TBC1D22A	3.15e-04	196	106	6	6057_DN
Drug	Benzthiazide [91-33-8]; Up 200; 9.2uM; PC3; HT_HG-U133A	NID2 SZT2 PON1 PTPRB STS RASSF4	3.15e-04	196	106	6	6607_UP
Drug	Nialamide [51-12-7]; Down 200; 13.4uM; MCF7; HT_HG-U133A	KDM4C GPR107 HSPA12A EFNA3 MAPK14 VASH2	3.15e-04	196	106	6	4347_DN
Drug	Solasodine [126-17-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A	KDM4C ARHGAP26 CUL9 FRMD1 CHST8 EFNA3	3.15e-04	196	106	6	3830_DN
Drug	Spectinomycin dihydrochloride [21736-83-4]; Up 200; 9.8uM; MCF7; HT_HG-U133A	ADAM18 CUL9 ADAMTS12 EFNA3 MAPK14 FADS2	3.15e-04	196	106	6	4773_UP
Drug	Meglumine [6284-40-8]; Down 200; 20.4uM; MCF7; HT_HG-U133A	CUL9 PTPRU SIM2 HSPA12A TBC1D22A VASH2	3.15e-04	196	106	6	6445_DN
Drug	Timolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A	SMURF1 NLGN1 TMEM62 MAPK14 TBC1D22A VCPIP1	3.15e-04	196	106	6	6483_DN
Drug	Carbachol [51-83-2]; Up 200; 21.8uM; MCF7; HT_HG-U133A	SZT2 SIM2 FRMD1 SEMA6D TBC1D22A RBFOX1	3.15e-04	196	106	6	3380_UP
Drug	2-MeNH	PON1 PON2	3.18e-04	6	106	2	CID000159841
Drug	aminoparathion	PON1 PON2	3.18e-04	6	106	2	CID000000220
Drug	7-hydroxytestosterone	SCD FADS2	3.18e-04	6	106	2	CID000065541
Drug	tris(p-nitrophenyl) phosphate	PON1 PON2	3.18e-04	6	106	2	CID000077473
Drug	vinyl phosphate	PON1 PON2	3.18e-04	6	106	2	CID000135020
Drug	Pm70	PON1 PON2	3.18e-04	6	106	2	CID006334707
Drug	diethyl 4-methylbenzylphosphonate	PON1 PON2	3.18e-04	6	106	2	CID000003050
Drug	nylon 11	PON1 PON2	3.18e-04	6	106	2	CID000017083
Drug	C19:0	SCD FADS2	3.18e-04	6	106	2	CID000012591
Drug	phosphinate	PON1 PON2 LBR MMP8	3.21e-04	70	106	4	CID000022497
Drug	Mexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A	CUL9 SIM2 GPR107 CHST8 EFNA3 TBC1D22A	3.24e-04	197	106	6	3862_DN
Drug	Piperidolate hydrochloride [129-77-1]; Up 200; 11.2uM; MCF7; HT_HG-U133A	FRMD1 EFNA3 STS SEMA6D RBFOX1 TENM1	3.24e-04	197	106	6	3551_UP
Drug	Glycopyrrolate [596-51-0]; Down 200; 10uM; PC3; HT_HG-U133A	ARHGAP26 CUL9 KDM4D HS2ST1 MYRF IQCK	3.24e-04	197	106	6	7386_DN
Drug	Methantheline bromide [53-46-3]; Up 200; 9.6uM; PC3; HT_HG-U133A	SMURF1 KCNIP1 FRMD1 FGF23 MMP8 MYRF	3.24e-04	197	106	6	5780_UP
Drug	Trichlorfon [52-68-6]; Up 200; 15.6uM; MCF7; HT_HG-U133A	JADE3 STS FAM168A TBC1D22A SCNN1A FADS2	3.24e-04	197	106	6	1675_UP
Drug	Aminopurine, 6-benzyl [1214-39-7]; Up 200; 17.8uM; HL60; HT_HG-U133A	NLGN1 OMD FGF23 STS KDM4B IQCK	3.24e-04	197	106	6	2351_UP
Drug	Vincamine [1617-90-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A	PON1 SIM2 OMD RBFOX1 FADS2 MMP8	3.24e-04	197	106	6	2327_UP
Drug	Tomatidine [77-59-8]; Up 200; 9.6uM; MCF7; HT_HG-U133A	CHST8 MAPK14 RBFOX1 TENM1 CATSPERB KDM4B	3.24e-04	197	106	6	2746_UP
Drug	Brinzolamide [138890-62-7]; Down 200; 10.4uM; MCF7; HT_HG-U133A	SMURF1 NLGN1 DIS3 EFNA3 TBC1D22A VASH2	3.24e-04	197	106	6	3230_DN
Drug	CP-319743 [172078-87-4]; Up 200; 10uM; PC3; HT_HG-U133A	SZT2 CORO2A KDM4C ATXN7L1 PTPRU C5	3.24e-04	197	106	6	7491_UP
Drug	LY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A	PTPRU FCHO1 MTRF1 EFNA3 TBC1D22A HS2ST1	3.24e-04	197	106	6	1641_DN
Drug	Mephenesin [59-47-2]; Down 200; 22uM; PC3; HT_HG-U133A	KDM4C GATA2 CUL9 MAPK14 MYRF IQCK	3.24e-04	197	106	6	7374_DN
Drug	valdecoxib; Down 200; 10uM; PC3; HT_HG-U133A	CORO2A GPR107 CHST8 EFNA3 MAPK14 MYRF	3.24e-04	197	106	6	6408_DN
Drug	Phenindione [83-12-5]; Up 200; 18uM; PC3; HT_HG-U133A	NID2 SMURF1 GPR107 EFNA3 TBC1D22A MYRF	3.24e-04	197	106	6	7289_UP
Drug	Enalapril maleate [76095-16-4]; Up 200; 8.2uM; PC3; HT_HG-U133A	GATA2 EFNA3 MAPK14 SCNN1A RASSF4 MYRF	3.24e-04	197	106	6	7265_UP
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; MCF7; HT_HG-U133A	SIM2 CHST8 EFNA3 SEMA6D TBC1D22A VCPIP1	3.24e-04	197	106	6	6026_DN
Drug	Alfadolone acetate [23930-37-2]; Up 200; 10.2uM; MCF7; HT_HG-U133A	CDHR2 ARHGAP26 CUL9 KCNIP1 ADAMTS12 EFNA3	3.24e-04	197	106	6	6506_UP
Disease	attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement	NLGN1 TENM2 TNNI3K HSPA12A CNTNAP5 MAPK14 SEMA6D FAM168A RBFOX1 ARID5B IGSF9B PRKDC KDM4B	4.97e-06	801	104	13	EFO_0003888, EFO_0007052, MONDO_0002491
Disease	age at menarche	PCSK2 CHAF1B TFAP2D KDM4C CHD2 TENM2 TNNI3K IGF2BP2 SEMA6D RBFOX1 KDM4B	8.25e-06	594	104	11	EFO_0004703
Disease	waist-hip ratio	NID2 TFAP2D ATXN7L1 CUL9 RFX4 CFAP65 IGF2BP2 FAM168A TBC1D22A RBFOX1 ARID5B PIPSL PHLDB2 IQCK PAQR7	2.59e-05	1226	104	15	EFO_0004343
Disease	attention deficit hyperactivity disorder, intracranial volume measurement	SEMA6D RBFOX1	3.68e-05	3	104	2	EFO_0003888, EFO_0004886
Disease	level of serum paraoxonase/arylesterase 1 in blood serum	PON1 PON2	3.68e-05	3	104	2	OBA_2044998
Disease	colorectal cancer	NID2 LAMA5 HSPA12A MRO RBFOX1 FADS2 DCLRE1A LRBA MYRF DCAF12	5.58e-05	604	104	10	MONDO_0005575
Disease	phosphatidylcholine measurement	KDM4C MS4A4A SCD RBFOX1 FADS2 MYRF SEZ6	6.81e-05	284	104	7	EFO_0010226
Disease	phosphatidylcholine (18:0/20:2, 20:0/18:2) measurement	FADS2 MYRF	7.35e-05	4	104	2	EFO_0800488
Disease	medulloblastoma (is_marker_for)	KDM4C KDM4B	1.22e-04	5	104	2	DOID:0050902 (is_marker_for)
Disease	nisinate (24:6n3) measurement	FADS2 MYRF	1.22e-04	5	104	2	EFO_0800536
Disease	level of Phosphatidylcholine (16:0_20:1) in blood serum	FADS2 MYRF	1.22e-04	5	104	2	OBA_2045073
Disease	level of Phosphatidylcholine (18:0_22:6) in blood serum	FADS2 MYRF	1.22e-04	5	104	2	OBA_2045097
Disease	periodontitis	NLGN1 TENM2 TTC6 IGF2BP2 RBFOX1 KDM4B	1.43e-04	223	104	6	EFO_0000649
Disease	neurodegenerative disease (implicated_via_orthology)	MARS2 RASA1 PON1 PON2 SCNN1A	1.66e-04	145	104	5	DOID:1289 (implicated_via_orthology)
Disease	1-arachidonylglycerol (20:4) measurement	FADS2 MYRF	1.83e-04	6	104	2	EFO_0800224
Disease	1-arachidonoylglycerophosphocholine measurement	FADS2 MYRF	1.83e-04	6	104	2	EFO_0021076
Disease	1-linoleoylglycerophosphoethanolamine measurement	FADS2 MYRF	1.83e-04	6	104	2	EFO_0021084
Disease	level of Phosphatidylethanolamine (O-16:1_20:4) in blood serum	FADS2 MYRF	1.83e-04	6	104	2	OBA_2045145
Disease	arachidonoylcholine measurement	FADS2 MYRF	1.83e-04	6	104	2	EFO_0800478
Disease	lysophosphatidylcholine 18:3 measurement	FADS2 MYRF	1.83e-04	6	104	2	EFO_0021454
Disease	1-docosapentaenoyl-GPC (22:5n3) measurement	FADS2 MYRF	1.83e-04	6	104	2	EFO_0800298
Disease	gondoic acid measurement	FADS2 MYRF	1.83e-04	6	104	2	EFO_0007975
Disease	level of Phosphatidylcholine (16:1_20:4) in blood serum	FADS2 MYRF	1.83e-04	6	104	2	OBA_2045084
Disease	smoking behavior	TENM2 TNNI3K IGF2BP2 SEMA6D FAM168A RBFOX1 ARID5B	2.11e-04	341	104	7	EFO_0004318
Disease	eicosapentaenoate (EPA; 20:5n3) measurement	FADS2 MYRF	2.55e-04	7	104	2	EFO_0800616
Disease	arachidonate 20:4n6 measurement	FADS2 MYRF	2.55e-04	7	104	2	EFO_0021063
Disease	1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) measurement	FADS2 MYRF	2.55e-04	7	104	2	EFO_0800391
Disease	level of Phosphatidylcholine (O-18:2_20:4) in blood serum	FADS2 MYRF	2.55e-04	7	104	2	OBA_2045135
Disease	1-eicosapentaenoyl-GPE (20:5) measurement	FADS2 MYRF	2.55e-04	7	104	2	EFO_0800353
Disease	pneumococcal meningitis	MRO TBC1D22A	3.40e-04	8	104	2	EFO_1001114
Disease	hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) measurement	FADS2 MYRF	3.40e-04	8	104	2	EFO_0800583
Disease	stearidonate 18:4n3 measurement	FADS2 MYRF	3.40e-04	8	104	2	EFO_0021075
Disease	1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6) measurement	FADS2 MYRF	3.40e-04	8	104	2	EFO_0800392
Disease	level of Phosphatidylethanolamine (O-18:1_18:2) in blood serum	FADS2 MYRF	3.40e-04	8	104	2	OBA_2045147
Disease	level of Phosphatidylethanolamine (O-18:2_20:4) in blood serum	FADS2 MYRF	3.40e-04	8	104	2	OBA_2045151
Disease	urate measurement, bone density	CHAF1B LAMA5 TENM2 GPR107 PEBP4 CNTNAP5 RBFOX1 ARID5B PRKDC	3.48e-04	619	104	9	EFO_0003923, EFO_0004531
Disease	1-arachidonoyl-GPE (20:4n6) measurement	FADS2 MYRF	4.36e-04	9	104	2	EFO_0800248
Disease	level of Phosphatidylcholine (O-18:0_20:4) in blood serum	FADS2 MYRF	4.36e-04	9	104	2	OBA_2045127
Disease	level of Phosphatidylcholine (O-18:1_18:2) in blood serum	FADS2 MYRF	4.36e-04	9	104	2	OBA_2045129
Disease	level of Phosphatidylcholine (O-18:1_20:3) in blood serum	FADS2 MYRF	4.36e-04	9	104	2	OBA_2045130
Disease	1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) measurement	FADS2 MYRF	4.36e-04	9	104	2	EFO_0800271
Disease	cognitive function measurement	GLDN TFAP2D SZT2 KDM4C CHD2 MS4A4A TNNI3K CNTNAP5 EFNA3 SEMA6D TBC1D22A RBFOX1 IGSF9B KDM4B	5.10e-04	1434	104	14	EFO_0008354
Disease	alopecia areata (is_marker_for)	KDM4C KDM4B	5.44e-04	10	104	2	DOID:986 (is_marker_for)
Disease	level of Phosphatidylcholine (O-18:2_16:0) in blood serum	FADS2 MYRF	5.44e-04	10	104	2	OBA_2045132
Disease	level of Phosphatidylethanolamine (O-18:1_20:4) in blood serum	FADS2 MYRF	5.44e-04	10	104	2	OBA_2045148
Disease	cholesteryl ester 22:4 measurement	FADS2 MYRF	5.44e-04	10	104	2	EFO_0021443
Disease	phosphatidylethanolamine ether measurement	FADS2 MYRF	5.44e-04	10	104	2	EFO_0010229
Disease	level of Phosphatidylcholine (O-16:1_20:4) in blood serum	FADS2 MYRF	6.63e-04	11	104	2	OBA_2045123
Disease	Tourette syndrome	OTUD1 PTPRU TENM2	7.39e-04	50	104	3	EFO_0004895
Disease	Drug habituation	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C0013170
Disease	Drug abuse	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C0013146
Disease	Prescription Drug Abuse	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C4316881
Disease	Substance-Related Disorders	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C0236969
Disease	Drug Use Disorders	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C0013222
Disease	Drug Dependence	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C1510472
Disease	Substance Dependence	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C0038580
Disease	Substance Use Disorders	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C0038586
Disease	Organic Mental Disorders, Substance-Induced	TENM2 HSPA12A SEMA6D XPO6	7.46e-04	115	104	4	C0029231
Disease	Substance abuse problem	TENM2 HSPA12A SEMA6D XPO6	7.70e-04	116	104	4	C0740858
Disease	linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] measurement	FADS2 MYRF	7.94e-04	12	104	2	EFO_0800500
Disease	level of Phosphatidylcholine (O-16:0_20:3) in blood serum	FADS2 MYRF	7.94e-04	12	104	2	OBA_2045115
Disease	cholesteryl ester 20:2 measurement	FADS2 MYRF	7.94e-04	12	104	2	EFO_0021440
Disease	dihomo-linolenoylcarnitine (C20:3n3 or 6) measurement	FADS2 MYRF	9.36e-04	13	104	2	EFO_0800547
Disease	level of Phosphatidylinositol (18:1_18:1) in blood serum	FADS2 MYRF	9.36e-04	13	104	2	OBA_2045159
Disease	level of Sphingomyelin (d34:2) in blood serum	FADS2 MYRF	9.36e-04	13	104	2	OBA_2045174
Disease	phosphatidylcholine ether measurement	FADS2 MYRF	9.36e-04	13	104	2	EFO_0010227
Disease	Hyperlipoproteinemia Type IIb	PON1 PON2	9.36e-04	13	104	2	C1704417
Disease	polyp of colon	NID2 LAMA5 FADS2	1.03e-03	56	104	3	MONDO_0021400
Disease	level of Phosphatidylcholine (18:1_20:2) in blood serum	FADS2 MYRF	1.09e-03	14	104	2	OBA_2045102
Disease	lysophosphatidylcholine 22:5 measurement	FADS2 MYRF	1.09e-03	14	104	2	EFO_0021462
Disease	diacylglycerol 38:4 measurement	FADS2 MYRF	1.09e-03	14	104	2	EFO_0020066
Disease	neutrophil count	DCPS ARHGAP26 GATA2 PIGV FCHO1 MSTO1 RBFOX1 VASH2 FADS2 PRKDC LRBA MYRF KDM4B	1.15e-03	1382	104	13	EFO_0004833
Disease	response to vaccine, cytokine measurement	TENM2 FRMD1 TENM1 DIP2C	1.21e-03	131	104	4	EFO_0004645, EFO_0004873
Disease	cis/trans-18:2 fatty acid measurement, trans fatty acid measurement	FADS2 MYRF	1.25e-03	15	104	2	EFO_0006821, EFO_0006824
Disease	oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] measurement	FADS2 MYRF	1.25e-03	15	104	2	EFO_0800508
Disease	level of Phosphatidylcholine (O-18:1_20:4) in blood serum	FADS2 MYRF	1.25e-03	15	104	2	OBA_2045131
Disease	phosphatidate measurement	FADS2 MYRF	1.25e-03	15	104	2	EFO_0020047
Disease	rheumatoid arthritis	ARHGAP26 MAPK14 RBFOX1 ARID5B FADS2 C5 MYRF	1.27e-03	462	104	7	EFO_0000685
Disease	lysophosphatidylcholine measurement	SCD FADS2 MYRF	1.38e-03	62	104	3	EFO_0010224
Disease	Hyperlipoproteinemia Type IIa	PON1 PON2	1.43e-03	16	104	2	C0745103
Disease	diacylglycerol 36:2 measurement	FADS2 MYRF	1.43e-03	16	104	2	EFO_0010355
Disease	phosphatidylcholine 38:3 measurement	FADS2 MYRF	1.43e-03	16	104	2	EFO_0010385
Disease	phosphatidylcholine 38:6 measurement	FADS2 MYRF	1.43e-03	16	104	2	EFO_0010388
Disease	level of Phosphatidylcholine (18:0_20:3) in blood serum	FADS2 MYRF	1.43e-03	16	104	2	OBA_2045093
Disease	neutrophil percentage of leukocytes	DCPS GATA2 MS4A4A ARID5B FADS2 PRKDC KDM4B DCAF12	1.44e-03	610	104	8	EFO_0007990
Disease	triacylglycerol 56:9 measurement	CNTNAP5 FADS2	1.62e-03	17	104	2	EFO_0010436
Disease	amyloid-beta measurement	ARHGAP26 CHD2 TENM2 NBAS RBFOX1 PRKDC	1.64e-03	355	104	6	EFO_0005194
Disease	Child Behaviour Checklist assessment	PCSK2 PEBP4	1.81e-03	18	104	2	EFO_0005661
Disease	triacylglycerol 56:3 measurement	NLGN1 FADS2	1.81e-03	18	104	2	EFO_0010430
Disease	level of Phosphatidylinositol (18:0_18:1) in blood serum	FADS2 MYRF	1.81e-03	18	104	2	OBA_2045155
Disease	diacylglycerol 36:3 measurement	FADS2 MYRF	1.81e-03	18	104	2	EFO_0020062
Disease	level of Phosphatidylcholine (16:0_22:5) in blood serum	FADS2 MYRF	1.81e-03	18	104	2	OBA_2045079
Disease	Hypercholesterolemia, Familial	PON1 PON2	1.81e-03	18	104	2	C0020445
Disease	breast cancer (is_implicated_in)	KDM4C PON1 MMP8 KDM4B	1.99e-03	150	104	4	DOID:1612 (is_implicated_in)
Disease	Lipoidosis	SCD FADS2	2.02e-03	19	104	2	C0023794
Disease	level of Phosphatidylethanolamine (18:0_20:4) in blood serum	FADS2 MYRF	2.02e-03	19	104	2	OBA_2045140
Disease	Juvenile Myelomonocytic Leukemia	ARHGAP26 GATA2	2.02e-03	19	104	2	C0349639
Disease	diacylglycerol 38:5 measurement	FADS2 MYRF	2.02e-03	19	104	2	EFO_0020067
Disease	diacylglycerol 38:3 measurement	FADS2 MYRF	2.02e-03	19	104	2	EFO_0020065
Disease	autism spectrum disorder (implicated_via_orthology)	CHD2 NLGN1 CNTNAP5 LRBA	2.09e-03	152	104	4	DOID:0060041 (implicated_via_orthology)

Protein segments in the cluster

Peptide	Gene	Start	Entry
HYVHSTPFGNYSFIC	TMEM62	171	Q0P6H9
FHPRSHFLYAYGNQI	CATSPERB	416	Q9H7T0
HCHYQGYAAEFPNSF	ADAM18	91	Q9Y3Q7
FPFGYVSNIHYHTLS	CHAF1B	336	Q13112
LNGSYTFIHLPYYFH	GLDN	356	Q6ZMI3
EPFADEYYGHLHVFT	FAM187A	156	A6NFU0
ITHPYEFDFYLCSHA	AGO3	741	Q9H9G7
PSYYHLHVHFTALGF	DCPS	271	Q96C86
HHYAAAYPSAYAPVS	CELF6	361	Q96J87
HLFGHYPAHDDFYLV	ATXN7L1	86	Q9ULK2
DASGHFLSYGLHYPI	ADAMTS12	61	P58397
YEFQHSHPAVTPDAY	TFAP2D	76	Q7Z6R9
EHFFHVFSGPRYYAF	MMP8	431	P22894
QHFSEEHYIFYFAGE	RASA1	546	P20936
GHFYNHKTSVFTPAY	RASSF4	171	Q9H2L5
SEYEHMQHFPGFAYI	RFX4	711	Q33E94
FHAIDYHYISSQGFP	GPR107	311	Q5VW38
FHGFSAEHYFPVSHF	IQCK	91	Q8N0W5
GVEFHYVYSHFLQFA	LBR	316	Q14739
AHSFRNHILGYFDYA	CACNA1F	896	O60840
YLPYNHQHEYFFLIG	FADS2	256	O95864
AFTEYVHAYFRGHSP	FCHO1	631	O14526
HYDAVFDHSYPNPEY	OTUD1	431	Q5VV17
HATSYAFHGLTPGYL	PTPRB	251	P23467
VFYGAAFYTNVLPHS	OR2T2	251	Q6IF00
FGSALAHFYYAIEPA	PAQR7	151	Q86WK9
PSYAPEFQFLHSAYA	FAM168A	46	Q92567
QALAHAYFAQYHDPD	MAPK14	301	Q16539
YFAGFEHHIPQYSLD	CFAP65	766	Q6ZU64
FPYLHYDATLPFHCS	MSTO1	316	Q9BUK6
PPAHSGFHRYQFFVY	PEBP4	141	Q96S96
TFPYGYHAGFNHGFN	KDM4B	271	O94953
ITFPYGYHAGFNHGF	KDM4C	271	Q9H3R0
FMVTFPYGYHAGFNH	KDM4D	271	Q6B0I6
TFPYGYHAGFNHGFN	KDM4E	271	B2RXH2
VPKFHYGTHYSTASF	LRBA	2296	P50851
LSHYHPEILQFFYAN	MRO	231	Q9BYG7
AIYLYCHQDFPGSSH	METTL15P1	216	P0C7V9
FHSFGYAARDFYHDL	HSPA12A	111	O43301
YHPFTTHSGYFSSLY	IGF2BP2	396	Q9Y6M1
FADGAPHYVAFYSNA	LAMA5	3196	O15230
HSNFGSPTYFYAFYH	NLGN1	516	Q8N2Q7
FSSHYPHGINTAIYH	NBAS	231	A2RRP1
AHHYNDFRFKTYAPV	PIP5K1A	131	Q99755
QFFPHGDASTYAHYL	KCNIP1	91	Q9NZI2
TPAHHYNAFRFKTYA	PIPSL	76	A2A3N6
YHVFSNLHPGTTYLF	PTPRU	551	Q92729
SATYLYLGHFHLDVF	PANX3	221	Q96QZ0
HAQAQYAYPGARFHI	NID2	946	Q14112
AVGPAHFYATNDHYF	PON2	171	Q15165
HFYATNDHYFSDPFL	PON2	176	Q15165
NVHHPSLFVAFYDYQ	PARP14	1776	Q460N5
SYVPAAAHDYSSGLF	GATA2	251	P23769
AHAGRYFEPHSYFPQ	FRMD1	201	Q8N878
HPYQYELNHFTPADA	EXOSC10	256	Q01780
DEYIYRHFFGHTFSP	CCPG1	726	Q9ULG6
HSYLDAYFVFPNGSA	CDHR2	1096	Q9BYE9
RYSHDFNFHINYGDL	HYOU1	486	Q9Y4L1
AFSLGYEFHAGHEYY	EFNA3	131	P52797
SFLSYLFHQHQLYGP	CHD2	521	O14647
FFPNAVYTHCYDSSG	DCAF12	416	Q5T6F0
ENGYDVYHSPQYHFL	FGF23	121	Q9GZV9
VPVFYVFHYLETGNH	C5	1016	P01031
HPTAANILFSAGYDY	CORO2A	141	Q92828
VHSAHNASGYFTIYG	DIP2C	1376	Q9Y2E4
GYYPGQLARLHFDHS	C1orf100	31	Q5SVJ3
NTFSLAFYSFHHPYC	MS4A4A	151	Q96JQ5
GLELATTFEHFYQHY	CUL9	1586	Q8IWT3
DHYAGLSKHFTFPVY	DCLRE1A	736	Q6PJP8
PGTYQRHYRNVFHAF	SLC25A35	36	Q3KQZ1
HFHHPMYGNCYTFND	SCNN1A	296	P37088
DSHHINPDSYYLFAD	JADE3	56	Q92613
YTEASYLHFPTFHAE	CNTNAP5	796	Q8WYK1
FFCFPHIHTIYYGEQ	OMD	351	Q99983
HFRTVPSNPHYFFYC	SZT2	1446	Q5T011
DSYGRVYAADPYHHA	RBFOX1	331	Q9NWB1
YLELFPAHLYFQAHG	PLEKHN1	116	Q494U1
FGCHPHFARYYSESQ	TATDN2	561	Q93075
EHFYGTNDHYFLDPY	PON1	176	P27169
PGFYHGHVSYLDFAK	HS2ST1	136	Q7LGA3
THYHPSNARFFTYGN	PITRM1	256	Q5JRX3
LAFLQGLFTFYHHGY	ARHGAP26	201	Q9UNA1
PLHHGFNYFYGISLT	STS	151	P08842
SYHYGHFPLDSHVFS	SIM2	441	Q14190
YHDTYPDFQVIIGFH	TENM1	2346	Q9UKZ4
GHHLQYFYSDLHNPT	TENM2	2316	Q9NT68
LNSFHYPDHSYKDQA	PHLDB2	986	Q86SQ0
NYTPADYGGLHHAAA	MTRF1	226	O75570
DFHHYGLASPIYTHF	DIS3	761	Q9Y2L1
FHGHYINGGFTVPFY	SMURF1	501	Q9HCE7
HGPYIFYKAFQFHLE	ARID5B	16	Q14865
SAFRDKFEHPNSYYH	CHST8	266	Q9H2A9
EHGYLYEHNFAFFPG	PIGV	76	Q9NUD9
DFPSLYDLGVHQYSH	ZNF341	511	Q9BYN7
THSHPACPLEFAYYF	ZSWIM9	121	Q86XI8
YSLAYFNAGNIYFHH	TTC6	381	Q86TZ1
FHHGQYYGYLSSSSP	IGSF9B	961	Q9UPX0
AGPGTFHFHYQAYLL	SEZ6	341	Q53EL9
SFKTYFSGNYFHHVV	VASH2	181	Q86V25
GFHNYHHSFPYDYSA	SCD	296	O00767
IFYVNAAPHIGHLYS	MARS2	51	Q96GW9
GIHPSLVADVHQYFY	VCPIP1	426	Q96JH7
TYQSEPDGFSHFHLY	TBC1D22A	441	Q8WUA7
SQGSVIHFSHGEYFY	PRKDC	1546	P78527
IHFSHGEYFYSLFSE	PRKDC	1551	P78527
LFKYTFHQPTHEGYF	XPO6	401	Q96QU8
PHFLHAIEYGNYVYF	SEMA6D	221	Q8NFY4
VFFTPLHIAAYYGHE	TNNI3K	166	Q59H18
GECGSYYNPHSDFHL	ZNF619	191	Q8N2I2
AQPATDYHFHFYRLC	MYRF	1136	Q9Y2G1
PFAEGLYHFYHNGLA	PCSK2	61	P16519